We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FTC Drops AndroGel Antitrust Case Against AbbVie, But Points to ‘Ill-Gotten Gains’
FTC Drops AndroGel Antitrust Case Against AbbVie, But Points to ‘Ill-Gotten Gains’
The Federal Trade Commission (FTC) has withdrawn the last count in its complaint against drugmaker AbbVie after the Supreme Court declined to review a ruling that the drugmaker used sham litigation to illegally maintain a monopoly on its testosterone drug AndroGel.